HB43
HB43 is a synthetic amphipathic cationic α-helical peptide, as well as an antibacterial/anticancer peptide. HB43 reduces the number of Methicillin (HY-121544)-resistant Staphylococcus aureus in biofilms in a dose-dependent manner. When loaded into chitosan nanoparticles, it achieves sustained release, and this effect is particularly pronounced under acidic conditions.
For research use only. We do not sell to patients.
- CAS No.: 932013-61-1
- Formula: C72H129N17O14
- Molecular Weight:1456.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
HB43 exhibits anti-cancer activity against MCF-7, SW480, BMKC, H1299, HeLa S3 and PC-3 cells. The LD50 of HB43 for these cells ranges from 6 to 15 μg/mL[1].
HB43 (108-216 μg/mL; 24 h), either free or loaded in P1-CNP, reduces MRSA USA300 LAC biofilm bacterial load and biomass in a dose-dependent manner; P1-CNP-loaded HB43 exhibits superior antibiofilm activity compared to free HB43, with the highest efficacy observed under acidic (pH 5.5) conditions[2].
HB43 (108-216 μg/mL; 24 h) disrupts the membrane integrity of MRSA USA300 LAC biofilm-embedded bacteria in a dose-dependent manner, with the highest membrane damage observed at 216 μg/mL[2].
HB43 (216 μg/mL; 2-4 h) penetrates MRSA USA300 LAC biofilms within 2 h and shows extensive uniform distribution across the biofilm surface by 4 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 932013-61-1
-
Molecular Weight 1456.90
-
Formula C72H129N17O14
-
SMILES
N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
-
Sequence
Phe-Ala-Lys-Leu-Leu-Ala-Lys-Leu-Ala-Lys-Lys-Leu-Leu
-
Sequence Shortening
FAKLLAKLAKKLL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Herrera-León C, et al. The impact of phosphatidylserine exposure on cancer cell membranes on the activity of the anticancer peptide HB43. The FEBS journal. 2022 Apr;289(7):1984-2003. [Content Brief]
[2]. Keikhosravani P, et al. Developing antibacterial HB43 peptide-loaded chitosan nanoparticles for biofilm treatment. International journal of biological macromolecules. 2025 May;310(Pt 2):143397. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HB43 Related Classifications
HY-P12121 Related Classifications
Powered by Bioz